Medivolve Inc. (OTC:COPRF) announces its subsidiary, Collection Sites, LLC, will provide free COVID-19 PCR tests to uninsured and undocumented patients through a government-funded HRSA program. Collection Sites will charge a fee per test while receiving $75-100 reimbursement from the program. The initiative begins in California, offering 24-hour results. The arrangement with Transplant Genomics supports high-complexity lab testing. Medivolve aims to enhance access to medical services as part of its strategy to tackle COVID-19.
Summary not available.
Medivolve Inc. has introduced multi-week custom testing solutions for a high school athletics department in Redlands, California, and a film production company in Los Angeles as part of its new business strategy. The company aims to expand its testing services across the U.S. Following solid sales results in February, with over 30,000 tests conducted, Medivolve CEO Doug Sommerville noted a shift towards business-focused custom testing solutions. An investor webinar is scheduled for March 23, 2021, to discuss recent developments.
Medivolve Inc. (OTC:COPRF) has signed a Letter of Intent to acquire a 100% equity stake in Modern Rx LLC, a Las Vegas-based pharmacy, enhancing its telehealth strategy. The $100,000 cash deal, supplemented by one million shares, aims to facilitate the direct filling of prescriptions for Collection Sites' telehealth patients. The acquisition is seen as crucial for expanding telehealth services as the program launches. Medivolve will host an investor webinar on March 23rd to discuss recent developments.
Medivolve Inc. (OTC:COPRF) has launched a partnership with Besser Brands in Florida, operating 9 Collection Sites. Besser Brands will manage all operational costs and pay royalties on tests sold. Additionally, Medivolve has completed the acquisition of Noble Bioscience Corp., gaining access to Nuturell’s Surface Shield technology, a COVID-19 disinfectant effective up to 90 days. This expansion positions Medivolve to enhance its COVID-19 testing capabilities amidst increasing demand.
Medivolve Inc. (OTC:COPRF) has cancelled its agreement to acquire Karland Health, LLC after due diligence showed the acquisition wouldn't be strategically beneficial. Medivolve's CEO, Doug Sommerville, emphasized that the company is still committed to its telehealth strategy, which will be elaborated on in a corporate update webinar scheduled for February 22 at 1 pm ET. Additionally, Medivolve completed a shares for debt settlement, issuing 10,958,024 common shares at $0.46 per share to settle $5.04 million in debt.
Medivolve Inc. (OTC:COPRF) announces an investor awareness campaign following its successful operational results, including the sale of 73,973 tests at an average price of $96 in January. To adapt to pandemic conditions, the company has shifted its marketing budget to digital efforts, partnering with Emerging Markets Consulting and Winning Media for comprehensive investor relations services. The campaign aims to enhance visibility in the telehealth market and support ongoing COVID-19 testing initiatives at its Collection Sites subsidiary.
Medivolve Inc. (OTC:COPRF) is hosting a webinar on February 22 at 1 pm ET to update investors on its telehealth strategy and recent business developments. The webinar will feature CEO Doug Sommerville and Dr. Glenn Copeland.
Additionally, Tim Shelburn, President of Collection Sites, is stepping down from his executive role but will remain as an advisor during the leadership transition. Collection Sites specializes in COVID-19 testing, providing rapid antibody and antigen tests.
Medivolve Inc. has signed a binding letter of intent to acquire Karland Health, LLC, aiming to enhance its healthcare service offerings. The transaction involves issuing 20 million common shares in exchange for a 100% stake. Additionally, Medivolve will settle $5,040,691 of its debts through the issuance of approximately 10.96 million shares at $0.46 each. This acquisition will allow Medivolve to integrate telehealth services and expand its COVID-19 testing capabilities, further emphasizing its commitment to accessible healthcare.
Medivolve Inc. (OTC:COPRF) announces the launch of new COVID-19 testing centers in Texas, Florida, and North Carolina, expanding its network to 62 sites. In January, the company sold 73,973 COVID-19 tests at an average price of $96, with 52% cash pay sales. A webinar on February 4 will discuss recent developments, featuring CEO Doug Sommerville. Medivolve is also acquiring up to 40% of Marvel Diagnostics for up to $1 million to enhance its testing capabilities. The company emphasizes the importance of increased testing for combating COVID-19.